Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.50 |
| ▸ | RELA | Q04206 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29029409 | 0.73 | TSHR (0.44) | NFKB1NFKB2RELATSHRALDH1A1 | |
| SCHEMBL8074509 | 0.70 | TSHR (0.41) | NFKB1NFKB2RELATSHRCCR6 | |
| SCHEMBL20786806 | 0.68 | PTPN1 (0.46) | TSHRALDH1A1L3MBTL1 | |
| SCHEMBL28015795 | 0.67 | SLC6A2 (0.42) | NFKB1TSHRACHEALDH1A1KDM4E | |
| Pentanal SCHEMBL264255 | 0.66 | — | — | |
| SCHEMBL9461285 | 0.65 | TSHR (0.39) | NFKB1NFKB2RELATSHRALDH1A1 | |
| SCHEMBL27572070 | 0.65 | TYR (0.50) | NFKB1NFKB2RELATSHRFAAH | |
| SCHEMBL26089455 | 0.65 | TYR (0.50) | NFKB1NFKB2RELATSHRFAAH | |
| SCHEMBL27636950 | 0.65 | TYR (0.50) | NFKB1NFKB2RELATSHRFAAH | |
| SCHEMBL27825897 | 0.65 | TYR (0.50) | NFKB1NFKB2RELATSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006151879-A | ANGIOGENESIS INHIBITOR | UNIV OF TOKUSHIMA | 2006-06-15 | — | — | JP | disclosed |
| US-20030186941-A1 | Cyclopenteneone derivatives | CHARTERHOUSE THERAPEUTICS LTD. (GB) | 2003-10-02 | — | — | US | disclosed |
| EP-1240171-A1 | CYCLOPENTENEONE DERIVATIVES | Charterhouse Therapeutics Ltd. (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044254-A1 | CYCLOPENTENEONE DERIVATIVES | CHARTERHOUSE THERAPEUTICS LTD. (GB) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186941-A1 | Cyclopenteneone derivatives | HAVCR2, ZC3HAV1, MALT1 | NFKB1 232/4885NFKB2 181/4885RELA 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.